Latest Conference Articles

December 9th 2021, 8:38pm

San Antonio Breast Cancer Symposium

Pyrotinib plus capecitabine exhibited longer overall survival (OS), compared with lapatinib plus capecitabine, in patients with HER2-positive breast cancer

December 9th 2021, 5:55pm

ASH Annual Meeting and Exposition

Not only is the 2021 ASH Annual Meeting bursting with more than 5000 abstracts unveiling pivotal data across a range of hematologic malignancies and disorders, but the conference will be held as a hybrid format after going fully virtual in 2020.

December 9th 2021, 5:41pm

San Antonio Breast Cancer Symposium

Prior research has shown that the combination of trastuzumab deruxtecan plus pertuzumab may be superior to T-trastuzumab deruxtecan alone in patients with HER2-positive metastatic breast cancer and the combination is now under examination in the phase 3 DESTINY-Breast09 trial.

December 9th 2021, 5:31pm

San Antonio Breast Cancer Symposium

Adjuvant treatment with neratinib or ado-trastuzumab emtansine resulted in a greater reduction in the risk of disease recurrence compared with other therapies in an epidemiologic model of HER2-positive, early-stage breast cancer.

December 9th 2021, 2:41pm

San Antonio Breast Cancer Symposium

The addition of the bispecific antibody zanidatamab to single-agent chemotherapy was found to produce promising antitumor activity with acceptable tolerability in heavily pretreated patients with HER2-positive breast cancer.

December 8th 2021, 10:40pm

San Antonio Breast Cancer Symposium

Significant outcome differences were observed in premenopausal vs postmenopausal patients with hormone receptor–positive, HER2-negative breast cancer who had 1 to 3 positive lymph nodes and received adjuvant chemotherapy as well as endocrine therapy.

December 8th 2021, 10:39pm

San Antonio Breast Cancer Symposium

A non-chemotherapy–based targeted regimen comprised of tucatinib, palbociclib, and letrozole resulted in prolonged central nervous system progression-free survival in patients with hormone receptor–positive, HER2-positive breast cancer.

December 8th 2021, 10:05pm

San Antonio Breast Cancer Symposium

Aromatase inhibitors significantly reduced the risk of breast cancer recurrence in premenopausal women with estrogen receptor–positive breast cancer receiving ovarian suppression compared with tamoxifen.

December 8th 2021, 9:12pm

San Antonio Breast Cancer Symposium

Black patients with breast cancer were more likely to experience treatment modifications or discontinuations in the neoadjuvant setting compared with White patients.

December 8th 2021, 8:22pm

San Antonio Breast Cancer Symposium

Kevin Kalinsky, MD, MS, discusses updated results from the phase 3 RxPONDER trial in patients with hormone receptor-positive, HER2-negative breast cancer.

December 8th 2021, 7:12pm

San Antonio Breast Cancer Symposium

First-line treatment with ribociclib/letrozole improved overall survival over placebo in patients with postmenopausal, hormone receptor–positive, HER2-negative advanced breast cancer, irrespective of metastatic site, number of sites, or prior (neo)adjuvant chemotherapy and endocrine therapy.

December 8th 2021, 6:40pm

San Antonio Breast Cancer Symposium

Survey data collected from more than 1400 laboratories around the world have demonstrated poor agreement in the evaluation of patients with breast cancer who have a low HER2 immunohistochemistry score of 0 or 1+ using standard HER2 assays.

December 8th 2021, 5:40pm

San Antonio Breast Cancer Symposium

Higher Oncotype DX recurrence scores were associated with prolonged persistence to 5 years of endocrine therapy vs lower Oncotype DX recurrence scores in patients with low-risk, estrogen receptor-positive/progesterone receptor–positive breast cancer, according to findings from a retrospective review.

December 8th 2021, 5:02pm

San Antonio Breast Cancer Symposium

Aileen I. Fernandez, PhD, discusses the results of a study examining low HER2 expression in breast cancer.

December 8th 2021, 2:58pm

San Antonio Breast Cancer Symposium

Datopotamab deruxtecan showed highly encouraging and durable efficacy through overall response rates in patients with advanced or metastatic triple-negative breast cancer.

December 7th 2021, 10:48pm

San Antonio Breast Cancer Symposium

The combination of entinostat and exemestane led to a significant improvement in progression-free survival compared with placebo and exemestane in Chinese patients with advanced hormone receptor–positive breast cancer.

December 7th 2021, 10:10pm

San Antonio Breast Cancer Symposium

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab resulted in a statistically significant and clinically meaningful improvement in event-free survival in patients with early-stage triple negative breast cancer.

December 7th 2021, 9:38pm

San Antonio Breast Cancer Symposium

Adding adjuvant palbociclib to standard endocrine therapy did not improve outcomes in patients with stage II to III hormone receptor–positive, HER2-negative early breast cancer.

December 7th 2021, 9:08pm

San Antonio Breast Cancer Symposium

Pembrolizumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival and overall survival vs chemotherapy alone in patients with previously untreated, locally recurrent, inoperable, or metastatic triple-negative breast cancer who have a PD-L1 combined positive score of 10 or higher.

December 7th 2021, 7:21pm

San Antonio Breast Cancer Symposium

Metformin failed to improve invasive disease-free survival or overall survival when used as adjuvant treatment in patients with early breast cancer, irrespective of estrogen or progesterone receptor status.